6533b86dfe1ef96bd12c9b95
RESEARCH PRODUCT
Treatment of macular oedema (excluding age-related macular degeneration (AMD))
Catherine Creuzot-garchersubject
Inflammation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyOCT[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansDiabetesŒdème maculaire OCT Diabète Occlusion veineuse Inflammation VEGF CorticoïdesCorticoidsMacular oedemaVEGFVenous occlusiondescription
Macular oedema corresponds to an increase in macular thickness most often associated with a rupture of the hematoretinal barriers. Diagnosis is based on the notion of reduced vision, but above all on multimodal imaging in which optical coherence tomography (OCT) plays an essential role both for the initial diagnosis and for follow-up. The mechanisms involved in the occurrence of macular oedema are primarily vascular endothelial growth factor (VEGF) and cytokines regardless of the aetiology of the oedema. Treatment often involves a combination of local treatment - primarily intravitreal injections of anti-VEGF or corticosteroids - and, in certain situations, such as diabetes or uveitis, general treatment. The principle of treatment is to try to treat the oedema while the tissue damage is not too severe. The analysis of the aetiology defines the therapeutic modalities. Certain investigations may be indicated when the presentations or the evolution under treatment remain atypical.
year | journal | country | edition | language |
---|---|---|---|---|
2021-01-01 |